FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder

https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-changes-labeling-transmucosal-buprenorphine-products-indicated-treat-opioid-use?utm_source=SAMHSA&utm_campaign=6664a7e556-EMAIL_CAMPAIGN_2024_12_26_07_27&utm_medium=email&utm_term=0_-6664a7e556-167840245